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Natural resistance to HIV-1 infection is influenced by genetics, viral-exposure, and 
endogenous immunomodulators such as vitamin D (VitD), being a multifactorial 
phenomenon that characterizes HIV-1-exposed seronegative individuals (HESNs). We 
compared mRNA expression of 10 antivirals, 5 immunoregulators, and 3 VitD pathway 
genes by qRT-PCR in cells of a small cohort of 11 HESNs, 16 healthy-controls (HCs), 
and 11 seropositives (SPs) at baseline, in response to calcidiol (VitD precursor) and/
or aldithriol-2-(AT2)-inactivated HIV-1. In addition, the expression of TIM-3 on T and 
NK cells of six HCs after calcidiol and calcitriol (active VitD) treatments was evaluated 
by flow cytometry. Calcidiol increased the mRNA expression of HAVCR2 (TIM-3; 
Th1-cells inhibitor) in HCs and HESNs. AT2-HIV-1 increased the mRNA expression 
of the activating VitD enzyme CYP27B1, of the endogenous antiviral proteins MX2, 
TRIM22, APOBEC3G, and of immunoregulators ERAP2 and HAVCR2, but reduced 
the mRNA expression of VitD receptor (VDR) and antiviral peptides PI3 and CAMP in 
all groups. Remarkably, higher mRNA levels of VDR, CYP27B1, PI3, CAMP, SLPI, and 
of ERAP2 were found in HESNs compared to HCs either at baseline or after stimuli. 
Furthermore, calcitriol increases the percentage of CD4+ T cells expressing TIM-3 
protein compared to EtOH controls. These results suggest that high mRNA expression 
of antiviral and VitD pathway genes could be genetically determined in HESNs more 
than viral-induced at least in peripheral blood mononuclear cells. Moreover, the virus 
could potentiate bio-activation and use of VitD, maintaining the homeostasis of the 
immune system. Interestingly, VitD-induced TIM-3 on T cells, a T cell inhibitory and 
anti-HIV-1 molecule, requires further studies to analyze the functional outcomes during 
HIV-1 infection.
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inTrODUcTiOn
The hallmark of the resistant phenotype exhibited by HIV-
exposed seronegative individuals (HESNs) seems to be a potent 
but focused and tightly regulated innate antiviral response, clear-
ing the virus while avoiding excessive immune activation and 
thus the susceptibility of target cells (1–3).
Antiviral factors such as Elafin (encoded by PI3 gene) (4, 5), 
secretory leukocyte protease inhibitor (SLPI) (6), defensins (3, 7, 8), 
cathelicidin (encoded by CAMP gene) (8), APOBEC3G (5, 9), and 
some members of the antiviral ribonuclease A family (RNases) (3, 
5) have been demonstrated to play a role in the natural resistance 
exhibited by HESNs. Furthermore, some reports have shown that 
T-cell immunoglobulin and mucin domain 3 (TIM-3) (encoded by 
HAVCR2 gene), a negative regulator of the activation of Th1 and 
Th17 cells (10, 11) can reduce HIV-1 infection in vitro (12, 13). Yet, a 
negative role during chronic progressive HIV-1 infection cannot be 
ruled out since it has been reported TIM-3 may dampers cytotoxic-
ity of CD8+ T cells in chronically HIV-1-infected subjects (14).
Recently, we and other authors have reported that Vitamin D 
(VitD), a key immunoregulatory element capable of decreasing 
inflammation while inducing the expression of antimicrobial 
peptides (15, 16), reduces HIV-1 infection in  vitro (17–19). 
This effect is most likely mediated by the induction of an HIV-
1-restrictive less proliferative immunophenotype, reducing 
viral co-receptor expression while promoting the expression of 
antiviral genes.
Interestingly, higher plasma VitD levels and higher mRNA 
expression of VitD receptor (VDR) were found in blood and 
mucosa from Colombian HESNs compared to unexposed healthy 
controls (HCs) (20). Furthermore, VDR mRNA expression was 
positively correlated with the expression of antiviral molecules 
in HESNs (8, 20).
The immune cells are endorsed with the metabolic machinery 
such as the 1α-hydroxilase (CYP27B1) and the VDR, allowing the 
bio-activation and use of precursor forms of VitD. This in turn 
promotes the transcription of genes having VitD response ele-
ments (VDREs) in their genomic sequences, such as CYP24A1, 
a well-known VitD-target gene (21, 22). However, whether an 
effective bio-activation of VitD results in the expression of anti-
viral molecules in immune cells from HESNs has not been estab-
lished yet. Furthermore, since the resistant phenotype could be 
naturally manifested by genetic predetermination or triggered by 
viral exposure, differences in RNA expression of immunoregula-
tory, antiviral, and VitD-related genes was explored in peripheral 
blood mononuclear cells (PBMCs) of HESNs compared to HCs 
and seropositives (SPs) from an Italian cohort.
MaTerials anD MeThODs
study Population
Blood samples were collected from 11 Italian HESNs, their HIV-
infected partners (SPs), and from 16 HCs enrolled at the Santa 
Maria Annunziata Hospital in Florence. Inclusion criteria for the 
HESNs were a history of multiple unprotected sexual episodes 
for more than 4  years at the time of enrollment, with at least 
three episodes of at-risk intercourse within 4  months prior to 
study entry, and an average of 30 (range, 18 to >100) reported 
unprotected sexual contacts per year with a SP partner. Infection 
in HESNs and HCs subjects was ruled out by plasma HIV RNA 
analyses. None of the subjects included in the study were intra-
venous drug users.
We have been following this cohort of individuals for the 
past 12 years (it was established in Tuscany in 1997). Both, the 
HESNs and HCs are involved in monogamous heterosexual 
relationships, are part of long-lasting couples, and have very 
similar sexual activities. The HESNs, SPs, and HCs have similar 
demographic background: age (mean years ± SD: 51.3 ± 9.2 for 
HESNs; 51.9 ± 9.2 for SPs, and 47.7 ± 12.9 for HCs), gender (36.4, 
63.6, and 45.4%, males for HESNs, SPs, and HCs, respectively), 
and citizenship as well as share the same genetic background 
(European–Tuscan ascendancy) and the same exposure to 
environmental factors. The presence of any chronic disease was 
an exclusion criterion when the HESN and HC were recruited 
and no other pathologies were detected at sampling in any of the 
individuals.
In the SP patients, the median (range) of CD4 cell counts were 
575 cells/mL (222–1,184 cells/mL), and viral loads were under 
the detection limit (>20 copies/mL). All the patients were under-
going antiretroviral (ARV) treatment at the time of the study.
In addition, samples of 6 Colombian HCs were also included 
to analyzed TIM-3 expression by flow cytometry. The study was 
designed and performed according to the Helsinki declaration 
(1975 revised in 2000) and was approved by the Ethics Committee 
of the Hospital S. Maria Annunziata. All subjects provided writ-
ten informed consent to participate in this study.
aT2-inactivated hiV-1 Viral stimuli assays
The PBMCs were isolated by centrifugation on a Ficoll discontin-
uous density gradient (Lympholyte-H, Cederlane Laboratories). 
After viability assessment, 2 × 106 PBMCs were resuspended in 
RPMI 1640 medium (Euroclone, Milan, Italy) supplemented 
with 20% fetal bovine serum (FBS) (Life sciences), and cal-
cidiol [25(OH)D; VitD precursor] (Sigma-Aldrich) at 100  ng/
mL (250  nM) [within the physiological range: 32–100  ng/mL 
(23)] or EtOH 0.01% v/v as vehicle control for 24 h. Subsequently, 
1 ×  106  cells were stimulated for 24  h with or without 300  ng 
of Aldrithiol-2 (AT2)-inactivated R5-tropic HIV-1Ba-L p24 
equivalents, maintaining their respective calcidiol- or EtOH-
supplemented medium. Inactivation of HIV-1 with AT-2 renders 
the virus reverse transcription deficient while preserving the 
functional integrity of the envelope (24). The cells were harvested 
24 h posttreatment and kept at −80°C in Isol-RNA lysis reagent 
(5Prime, Hilden, Germany) until RNA extraction.
real-time retro-Transcribed (rT)-Pcr to 
Test calcidiol effects on gene expression
A total of 18 genes, belonging to the VitD pathway (CYP27B1, 
CYP24A1, and VDR), antiviral response (APOBEC3G, SLPI, 
PI3, TRIM22, RNASE4, ANG, CAMP, CH25H, and MX2), and 
immunoregulators (HAVCR2, FOXP3, NFKBIA, ERAP2, and 
TLR2) as well as the viral co-receptor CCR5 were selected for 
gene expression assays for their relevance in the context of HIV-1 
infection [reviewed in Ref. (3, 8, 20, 25, 26)].
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The RNA was extracted by Isol-RNA lysis reagent (5Prime) 
from freshly isolated unstimulated PBMCs (baseline condi-
tion) as well as from PBMCs treated with calcidiol/EtOH alone 
or calcidiol/EtOH plus AT2-HIV-1. Additionally, RNA from 
calcidiol- or EtOH-treated PBMCs of HCs, stimulated with LPS 
(Lipopolysaccharide) for 12 h (1 µg/mL, n = 6 in each group) were 
also analyzed as positive controls of CYP27B1 mRNA expression 
(27, 28). Following DNAse I treatment (Promega, Madison, WI, 
USA), RNAs were RT using the Moloney murine leukemia virus 
retro-transcriptase (Promega. Fitchburg, WI, USA), and reverse 
transcriptase negative controls were performed to rule out con-
tamination with genomic DNA in PCR amplifications. Real-time 
RT-PCRs were performed using the iTaq™ Universal SYBR 
Green® Supermix (Bio-Rad) (genes and primers are detailed in 
Table S1 in Supplementary Material), running melting curves to 
ensure specific amplification.
The results are presented as the median of the relative 
expression units (RUs) to the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), and hypoxanthine-guanine phospho-
ribosyltransferase (HPRT) reference genes calculated by the ΔCt 
method using the CFX manager 3.1 (Bio-Rad). Samples that did 
not amplify in the RT-PCR were excluded from the analysis of 
the respective gene. The number of samples and the median and 
interquartile range of mRNA expression of each gene in each 
condition is detailed in Table S1 in Supplementary Material.
Flow cytometry to Test calcidiol and 
calcitriol effects on TiM-3 expression 
on T and nK cells
In 96-well plates (BD, Franklin Lakes, NJ, USA), 100,000 viable 
PBMCs/well of 6 Colombian HCs were resuspended in 200 µL 
RPMI 1640 medium (Gibco, Grand Island, NY, USA) supple-
mented with 10% FBS and were treated with calcidiol at 250 nM 
and calcitriol (active form of VitD) at 0.5 nM (both within the 
physiological range) or with 0.01% v/v EtOH as vehicle control.
Cells were harvested 48  h posttreatments in polypropylene 
tubes, centrifuged at 700 ×  g for 5  min and washed with PBS. 
Extracellular staining was done with fluorochrome-labeled 
antibodies purchased from eBioscience (Santa Clara, CA, USA): 
fixable viability dye eFluor 506, anti-CD3 PE-Cy7, anti-CD4 
PE, anti-CD8 eFluor® 450, anti-CD56 PE-Cy7, and anti-TIM-3 
APC-Cy7. Samples were acquired on a BD-LSRFortessa™ flow 
cytometer, and data were analyzed in FACSDiva v.8.0.1 software. 
The gating strategies are shown in Figure S1 in Supplementary 
Material.
statistical analysis
Data were analyzed on the GraphPad Prism v.7.00 software. 
Normality was tested by the Shapiro–Wilk’s test. One-way 
ANOVA with post  hoc Bonferroni’s multiple comparisons or 
Kruskal–Wallis with Dunn’s multiple comparisons tests were 
used to compare differences in mRNA at baseline conditions 
between HESNs and HCs or vs. SPs and to compare differences 
in percentage and mean fluorescence intensity (MFI) of TIM-3 
in T  and NK cells between each of the VitD treatments and 
the vehicle control. Two-way ANOVA and post hoc Bonferroni’s 
multiple comparisons were used to compare differences between 
calcidiol and the vehicle controls as well as between HESNs vs. 
HCs and HESNs vs. SPs in AT2-HIV-stimulated or -unstimu-
lated cells. Paired t- or Wilcoxon-tests were used to compare 
differences in mRNA levels between AT2-HIV-stimulated and 
-unstimulated cells. The correlations between VDR mRNA and 
transcript levels of the molecules analyzed were evaluated using 
the Spearman coefficient rank (r). Two-tailed hypotheses were 
taken into account, and a p-Value <0.05 corrected by multiple 
testing was considered statistically significant. The results are 
presented as mean with 95% confidence interval or median with 
interquartile range. The open-access database of transcription 
factor binding profiles (http://jaspar.genereg.net/cgi-bin/jas-
par_db.pl) was used to find putative VDRE sequences in the 
genes potentially modulated by VitD in gene expression analysis.
resUlTs
hesns have a higher expression of VitD 
Pathway Molecules, suggestive of an 
active VitD Metabolism
We first tested for differences in mRNA expression of VitD 
pathway molecules VDR, CYP27B1, and CYP24A1 between 
HESNs vs. HCs or HESNs vs. SPs, which could suggest varia-
tions in the ability to metabolize calcidiol into the active form 
calcitriol. As shown in Figure 1A, CYP27B1 mRNA levels were 
higher, although not statistically significant, in HESNs compared 
to HCs at baseline conditions (means: 0.0094 vs. 0.0068 mRNA 
RU, respectively; p  =  0.0698). Nonetheless, CYP27B1 mRNA 
levels were significantly higher in HESNs than HCs after 48 h of 
culture in presence of both calcidiol and EtOH (means: 0.0623 vs. 
0.0261 mRNA RU, for HESNs and HCs, respectively; p = 0.0131). 
Moreover, similar to LPS, a known inducer of CYP27B1 expres-
sion (29), AT2-HIV-1 stimuli increased mRNA levels of this 
enzyme to similar levels (Figures 1A,B); this increase was higher 
in HESNs than HCs regardless calcidiol or EtOH treatments 
(means: 0.1251 vs. 0.0467 mRNA RU, for HESNs and HCs, respec-
tively; p = 0.0487. Figure 1A). Moreover, the AT2-HIV-induced 
increase in CYP27B1 mRNA was higher in previously infected SP 
individuals (235.3%; p < 0.00001), compared to HESNs (78.2%; 
p = 0.0056), and HCs (60.7%; p = 0.0003) (Figure 1B).
Similarly, as shown in Figure 1C, higher VDR mRNA levels 
were found in HESNs compared to HCs at baseline (means: 
0.2432 vs. 0.1477 mRNA RU, respectively; p  =  0.0232) and 
after 48 h of culture, regardless of calcidiol or EtOH treatments 
(means: 0.3995 vs. 0.2135 mRNA RU, for HESN and HCs, 
respectively; p = 0.0020). Furthermore, 48 h of calcidiol or EtOH 
increased the VDR mRNA levels taking into account all three 
groups (p = 0.0424 by two-way ANOVA), but no differences in 
VDR mRNA expression were observed between calcidiol and 
EtOH treatments nor between any of the groups studied after 
AT2-HIV-1 stimuli. However, the viral stimulus reduced mRNA 
expression of VDR in HESNs (42.4%; p =  0.0001) and in SPs 
(34.3%; p = 0.0002), but not in HCs (Figures 1C,D).
No differences in CYP24A1 mRNA expression were found 
in any of the conditions between the groups studied. Although 
FigUre 1 | hiV-exposed seronegative individuals (hesns) had a higher expression of vitamin D (VitD) pathway molecules, suggestive of an active 
VitD metabolism. Peripheral blood mononuclear cells (PBMCs) from HESNs, HCs, or seropositives (SPs) unstimulated (baseline, striped bars) or cultured with 
calcidiol 100 ng/mL (gray bars) or EtOH 0.01% v/v (white bars) with or without AT2-HIV-1 and mRNA of the VitD pathway genes CYP27B1 (a,B), VDR (c,D), 
and CYP24A1 (e) relative to the glyceraldehyde-3-phosphate dehydrogenase/hypoxanthine-guanine phosphoribosyltransferase mRNA levels were quantified by 
qRT-PCR. LPS-stimulated PBMCs from HCs (1 µg/mL, n = 6 in each group) were also analyzed as positive control for CYP27B1 mRNA expression. Differences 
between HESNs and HCs or vs. SPs in PBMCs at baseline were analyzed by Kruskal–Wallis for CYP27B1 mRNA and by one-way ANOVA for VDR and 
CYP27B1 mRNA. Differences between HESNs and HCs or vs. SPs as well as between calcidiol and EtOH treatments in mRNA expression in PBMCs stimulated 
with or without AT2-HIV-1 were analyzed by two-way ANOVA. Calcidiol and EtOH treatments were combined to analyze differences in the mRNA levels of 
CYP27B1 (B) and VDR (D) between AT2-HIV-stimulated (dotted bars) and -unstimulated cells (white bars) by paired t-test. Correlations between mRNAs of VDR 
and CYP27B1 (F) or CYP24A1 (g) in HESNs at baseline were evaluated using the Spearman coefficient rank (r). Bars correspond to means with CI 95%. ϕ45% 
increase: ϕp = 0.3192, #p = 0.0698, *p < 0.05, **p < 0.01 are presented.
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calcidiol increased by 45% mRNA levels of CYP24A1 in HESNs 
after AT2-HIV-1 stimulus, the difference was not significant 
(p = 0.3192; Figure 1E).
In addition, mRNA levels of VDR were positively corre-
lated with those of CYP27B1 at baseline conditions (r =  0.65, 
p = 0.0490; Figure 1F) and with those of CYP24A1 after calcidiol 
5Aguilar-Jimenez et al. Anti-HIV-1 Profile in HESNs
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plus AT2-HIV-1 stimuli only in HESNs (r =  0.77, p =  0.0214; 
Figure 1G).
hesns have higher expression of 
antiviral Factors compared to hcs
Higher mRNA levels of the CAMP were found in HESNs com-
pared to HCs at baseline conditions (medians: 0.1877 vs. 0.0572 
mRNA RU, respectively. p  =  0.0300; Figure  2A). Likewise, 
higher mRNA levels of the anti-protease PI3 (encoding elafin) 
were found in HESNs compared to HCs at baseline conditions 
(medians: 0.0176 vs. 0.0043 mRNA RU, respectively. p = 0.0134; 
Figure 2B), remaining higher in HESNs than HCs after 48 h cul-
ture, regardless of calcidiol or EtOH treatments (means: 0.0611 vs. 
0.0115 mRNA RU, for HESN and HCs, respectively, p = 0.0165; 
Figure 2B). There were no significant differences in the mRNA 
expression of CAMP and PI3 between the studied groups under 
any of the treatments after AT2-HIV-1 stimulus. Unexpectedly, 
the viral stimulus reduced mRNA expression of CAMP in HCs 
(63.8%; p < 0.0001), in HESNs (67.9%; p < 0.0001), and in SPs 
(76.3%; p < 0.0001) (Figure 2C). The viral stimulus also reduced 
mRNA expression of PI3 in HCs (48.6%; p = 0.0257), in HESNs 
(67.5%; p = 0.0015), but not in SPs (Figure 2D). In addition, 
after AT2-HIV-1 stimulus, CAMP mRNA positively correlate 
with the VDR mRNA in all individuals (r = 0.39, p = 0.0252; 
Figure 2E), but particularly, in HESNs (r =  0.71, p =  0.0182; 
Figure  2E). Interestingly, SLPI mRNA levels were higher in 
HESNs than HCs at baseline [0.0268 (n = 10) vs. 0.0136 (n = 9) 
mean mRNA RU; p =  0.5793], after calcidiol/EtOH [0.0595 
(n = 14) vs. 0.0085 (n = 12) mean mRNA RU; p = 0.3260] but 
only statistically significant after AT2-HIV-1 stimulus regard-
less calcidiol or EtOH treatments [0.0880 (n =  18) vs. 0.0151 
(n = 26) mean mRNA RU; p = 0.0497] (Figure 2F), although 
viral stimulus does not significantly modify the SLPI mRNA 
expression (Figure 2G).
In contrast, the mRNA levels of genes encoding the 
aminopeptidase ERAP2 and antivirals MX2, TRIM22, and 
APOBEC3G were similar between HESNs, HCs, and SPs at 
baseline and they were not modified by calcidiol treatment 
(Table S1 in Supplementary Material). However, the AT2-
HIV-1 stimulus increases significantly the mRNAs of ERAP2 
(1.8-fold, p <  0.0001 in HCs; 1.3-fold, p =  0.0178 in HESNs; 
1.4-fold, p = 0.0004 in SPs); of MX2 (11.7-fold, p < 0.0001 in 
HCs; 9.8-fold, p < 0.0001 in HESNs; 9.4-fold, p < 0.0001 in SPs); 
of TRIM22 (6.9-fold, p < 0.0001 in HCs; 4.9-fold, p < 0.0001 in 
HESNs; 5.5-fold, p < 0.0001 in SPs); and of APOBEC3G (2.0-
fold, p < 0.0001 in HCs; 1.8-fold, p < 0.0001 in HESNs; 1.8-fold, 
p <  0.0001 in SPs) (Figure  3). Furthermore, ERAP2 mRNA 
levels were significantly higher in HESNs than HCs (p = 0.0010) 
and SPs (p = 0.0099) after both calcidiol/EtOH and AT2-HIV-1 
stimuli (Figure 3A).
calcidiol stimulus increases the mrna 
levels of HAVCR2 (TiM-3)
Whereas HAVCR2 mRNA levels were not different between the 
groups studied at baseline, with or without AT2-HIV-1 stimuli, 
incubation with calcidiol increased the HAVCR2 mRNA levels 
by 40.6 and 23.9% without AT2-HIV-1 stimulus in HESNs 
(p =  0.0015) and HCs (p =  0.0420), respectively (Figure  4A). 
Likewise, calcidiol increased the HAVCR2 mRNA levels by 
29.4% with AT2-HIV-1 stimulus only in HESNs (p =  0.0080) 
(Figure 4A).
The AT2-HIV-1 stimulus also significantly increase the 
HAVCR2 mRNA levels by 43.3% in HCs (p < 0.0001), by 60.2% in 
HESNs (p < 0.0001), and by 26.5% in SPs (p = 0.0103) (Figure 4B).
Additionally, there were positive correlations between the 
mRNA of HAVCR2 and VDR at baseline conditions (r =  0.82, 
p < 0.0001 in all individuals and r = 0.94, p < 0.0001 in HESNs; 
Figure 4C) and after AT2-HIV-1 stimulus (r = 0.67, p < 0.0001 
in all individuals and r = 0.83, p = 0.0047 in HESNs; Figure 4D).
calcitriol stimulus increases the 
Percentage of TiM-3-expressing 
cD4+ T cells
Since we found a calcidiol-induced increase in the HAVCR2 
(TIM-3) mRNA, we also explored if this effect would be main-
tained at the protein level by evaluating the TIM-3 expression on 
T and NK cells of healthy controls by flow cytometry after both 
calcidiol (precursor of active VitD) and calcitriol (active VitD) 
treatments at physiological concentrations.
While in NK cells, any of the VitD treatments did not signifi-
cantly modify the TIM-3 expression (data not shown), the active 
(calcitriol), but not the precursor VitD (calcidiol), did significantly 
increase the percentage of CD4+ T cells-expressing TIM-3 pro-
tein compared to EtOH controls (4.14-fold, p = 0.0379; Figure 5).
DiscUssiOn
The natural resistance to HIV-1 infection exhibited by HESNs 
seems to be a genetically determined multifactorial phenomenon 
involving strong but well-controlled immune responses against 
HIV-1 possibly triggered by a frequent viral exposure (1–3).
Interestingly, several antiviral factors and effector mechanisms 
associated with resistance have been shown to be influenced by 
the VitD pathway (19, 20). Remarkably, similar to previous results 
in PBMCs and genital mucosa of HESNs from a Colombian 
cohort (20), higher mRNA levels of the VDR were observed in 
unstimulated PBMCs from HESNs compared to HCs; moreover, 
the calcidiol-to-calcitriol-activating enzyme CYP27B1 was also 
higher in HESNs (Figures  1A,C). These results support the 
participation of VitD pathway in the natural resistance to HIV-1 
infection and suggest an improved ability of HESNs to respond 
to VitD stimulus.
Yet, the effect of estrogens to the VDR expression could have 
slightly influenced our results due to the higher proportions of 
women in HESNs compared to HCs.
Even though in this study we explored the broad response in 
PBMCs, we expect the VDR expression should be higher within 
each immune cell subset of HESNs since several immune cells 
subpopulations that have improved functional capacities in 
HESNs (30) have been also enhanced by VitD (31–33).
FigUre 2 | higher expression of antiviral genes in hiV-exposed seronegative individuals (hesns) compared to hcs at baseline conditions, and after 
viral stimulus. Peripheral blood mononuclear cells (PBMCs) from HESNs, HCs, or seropositives (SPs) unstimulated (baseline, striped bars) or cultured with calcidiol 
100 ng/mL (gray bars) or EtOH 0.01% v/v (white bars) with or without AT2-HIV-1 and mRNA of the antiviral genes CAMP (n = 7–13) (a), PI3 (n = 6–10) (B), and 
secretory leukocyte protease inhibitor (SLPI) (n = 6–12) (F), relative to the glyceraldehyde-3-phosphate dehydrogenase/hypoxanthine-guanine 
phosphoribosyltransferase mRNA levels were quantified by qRT-PCR. Differences in mRNA expression between HESNs and HCs or vs. SPs in PBMCs at baseline 
were analyzed by Kruskal–Wallis. Differences between HESNs and HCs or vs. SPs as well as between calcidiol and EtOH treatments in mRNA expression in PBMCs 
stimulated with or without AT2-HIV-1 were analyzed by two-way ANOVA. A correlation between mRNAs of VDR and CAMP (e) in PBMCs under AT2-HIV/calcidiol 
stimuli were evaluated using the Spearman coefficient rank (r). Calcidiol and EtOH treatments were combined to analyze differences in the mRNA levels of CAMP 
(c), PI3 (D), and SLPI (n = 6–12) (g) between AT2-HIV-stimulated (dotted bars) and -unstimulated cells (white bars) by paired t-test. Bars correspond to means with 
CI 95%. *p < 0.05, **p < 0.01 are presented.
6
Aguilar-Jimenez et al. Anti-HIV-1 Profile in HESNs
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 136
Although, we did not measure calcitriol levels directly, HESNs 
seemed to be more responsive to viral stimulus than HCs increas-
ing CYP27B1 mRNA levels. This in turns could favor the calcidiol-
to-calcitriol conversion, supporting the 45% yet not significant 
increase in CYP24A1 mRNA levels in HESNs by the less bioactive 
calcidiol (34, 35) and its positive correlation with VDR mRNA, as 
previously proposed (17, 19) (Figure 1). The kinetics in CYP24A1 
expression may explain the absence of a significant increase. 
FigUre 3 | Viral stimulus increase expression of the aminopeptidase ERAP2 and antiviral genes in all studied groups. Calcidiol- and EtOH-treated 
peripheral blood mononuclear cells from HESNs, HCs, or seropositives (SPs) were combined to analyze differences in the mRNA levels of ERAP2 (n = 20–28) (a), 
MX2 (n = 21–29) (B), TRIM22 (n = 21–28) (c), and APOBEC3G (n = 21–29) (D) between AT2-HIV-stimulated (dotted bars) and -unstimulated cells (white bars) by 
paired t-test or Wilcoxon test in the case of TRIM22. Furthermore, differences between HESN and HCs or SPs in the mRNA levels of these genes were analyzed by 
ANOVA with multiple comparisons post hoc. Bars correspond to means. The viral-induced fold induction is shown. *p < 0.05, **p < 0.01, ***p < 0.001, and 
****p < 0.0001 are presented.
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Indeed, it has been observed that CYP24A1 expression in T cells 
peak after 48 h of VitD treatment (21), compared to the 24 h point 
in time that we analyzed here. Previous studies demonstrated 
that calcidiol-to-calcitriol conversion results in antiviral activity 
against hepatitis C virus activity (36), supporting our assumption.
Since the high expression of antiviral factors are part of the 
resistant phenotype in HESNs, we explored potential differences 
in the mRNA expression of several antiviral factors between the 
groups studied (Table S1 in Supplementary Material). Our results 
suggest that the viral stimulus triggers the expression of antiviral 
factors known playing a role in resistance to HIV-1 infection such 
as ERAP2, MX2, TRIM22, and APOBEC3G (Figure 3), suggesting 
that the frequent viral exposure in HESNs could induce higher 
levels of these molecules as particularly observed for APOBEC3G 
and MX2 in several cohorts of HESNs (5, 9, 37).
However, other antiviral factors such as CAMP, PI3, SLPI, and 
ERAP2 were significantly higher in HESNs compared to HCs 
at baseline as previously described in other sexually exposed 
cohorts (PBMCs and mucosa) (4, 5, 8), which is maintained inde-
pendently of additional stimuli (Figures 2 and 3A). Although the 
differences in SLPI mRNA were statistically significant only after 
AT2-HIV-1 stimulus, this is most likely due to higher sample size 
since viral stimulus does not significantly modify the SLPI mRNA 
expression (Figure 2G). Interestingly, the viral stimulus in vitro 
reduced mRNA expression not only of VDR (Figure  1D), but 
also of the antiviral genes CAMP and PI3 (Figures 2C,D) 24 h 
after viral challenge, as observed in other antivirals by co-evolved 
mechanisms (38), suggesting their high expression in HESNs, 
could be naturally manifested by genetic determination rather 
than viral-induced at least in PBMCs. Although the expression 
of these genes could be also genetically induced in other tissues 
such as anal/genital mucosa or oral compartments, differences 
in the expression pattern due to the frequent long lasting HIV-1 
exposure could not be ruled out.
Despite the fact that the CAMP gene has putative VDREs in its 
promoter (15), calcidiol treatment was not enough to significantly 
FigUre 4 | calcidiol increases the mrna levels of HAVCR2. Aligned dot plots show the mRNA levels of HAVCR2 (n = 9–14) (a), relative to the 
glyceraldehyde-3-phosphate dehydrogenase/hypoxanthine-guanine phosphoribosyltransferase mRNA expression in peripheral blood mononuclear cells (PBMCs) 
from HIV-exposed seronegative individuals (HESNs), HCs, or SPs unstimulated (baseline, striped bars) or cultured with calcidiol 100 ng/mL (gray bars) or EtOH 
0.01% v/v (white bars) with or without AT2-HIV-1. Differences in mRNA expression between HESNs and HCs or vs. SPs in PBMCs at baseline were analyzed by 
one-way ANOVA. Differences between HESNs and HCs or vs. SPs as well as between calcidiol and EtOH treatments in mRNA expression in PBMCs stimulated 
with or without AT2-HIV-1 were analyzed by two-way ANOVA. Calcidiol and EtOH treatments were combined to analyze differences in the mRNA levels of HAVCR2 
(n = 19–26) (B) between AT2-HIV-stimulated (dotted bars) and -unstimulated cells (white bars) by paired t-test. Correlations of VDR mRNA with mRNAs of HAVCR2 
in PBMCs at baseline (c), and of HAVCR2 in PBMCs under AT2-HIV/Calcidiol stimuli (D), were evaluated using the Spearman coefficient rank, r. Bars correspond to 
means with CI 95%. *p < 0.05, **p < 0.01, and ****p < 0.0001 are presented.
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increase its mRNA expression neither before nor after the viral 
stimulus in any of the groups evaluated. One possibility is that the 
HIV-1 stimulus alone is insufficient to produce a sizable calcidiol-
to-calcitriol conversion, capable of modulating antiviral genes as 
observed when PHA/IL-2 stimulus was used (19); nevertheless, 
there was a 40% increase in CAMP mRNA along with a significant 
positive correlation of CAMP mRNA levels with those of VDR in 
HESNs (Figure 2C).
On the other hand, whereas no differences in mRNA levels of 
HAVCR2 (encoding TIM-3) were found between HESNs, HCs, 
and SPs either at baseline or after viral stimulus, calcidiol treat-
ment induced a significant increase in their expression mainly 
in HESNs regardless of the presence of the virus (Figure 4A). 
The induction of VitD over HAVCR2 mRNA expression was also 
supported by the presence of putative VDREs in the genomic 
region of this gene (Table S1 in Supplementary Material, 
verified at http://jaspar.genereg.net/cgi-bin/jaspar_db.pl) and by 
positive correlations between VDR and HAVCR2 mRNA levels 
(Figures 4C,D).
Moreover, we found that the active (calcitriol) at physiological 
concentration, but not the precursor VitD (calcidiol), significantly 
increases the percentage of CD4+ T cells-expressing TIM-3 pro-
tein compared to EtOH controls (Figure 5). Since calcidiol need 
to be first converted into calcitriol before it can induce changes 
in gene expression could explain why a 48 h calcidiol treatment 
increases HAVCR2 mRNA expression but not the protein levels 
yet, while 48 h treatment of calcitriol, being already active, was 
enough to observe an increase in the TIM-3 protein levels.
TIM-3 has been identified mainly as a negative regulator of 
Th1 and Th17 cell responses (10, 11, 39). However, other reports 
have provided evidence that under acute stimulation, Tim-3 can 
promote an effector phenotype in CD8+ T cells (40) and NK 
cells (41).
Similarly, its role during HIV-1 infection is not clear, since 
TIM-3 has been associated with susceptibility, exhaustion, and 
progression (42, 43), while other studies have suggested that 
TIM-3 blocks the release of HIV-1 in  vitro (12, 13). Since we 
have observed that VitD has anti-HIV-1 activity in vitro (19), the 
FigUre 5 | calcitriol increases the percentage of TiM-3-expressing 
cD4+ T cells. Peripheral blood mononuclear cells from six healthy donors 
were treated with calcidiol at 250 nM, calcitriol (light gray bars) at 0.5 nM 
(dark gray bars), or with 0.01% v/v EtOH (white bars) as vehicle control for 
48 h and the percentage of CD4+ (a) and CD8+ (B) T cells-expressing 
TIM-3 were assessed by flow cytometry. Differences were compared by 
One-way ANOVA with post hoc Bonferroni’s multiple comparisons. Bars 
correspond to means with CI 95%. *p < 0.05 is presented.
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participation of TIM-3 in the VitD-mediated protection could 
not be ruled out.
Although the well-characterized cohort of HESNs evaluated 
in this study could compensate the small sample size limitation, 
further evaluations with a higher sample size, mRNA evaluations 
at early time points, and with protein quantification are required 
to confirm these results.
Despite this limitation, our results suggest that HESNs had 
higher responsiveness to viral and VitD stimuli compared to HCs, 
by promoting bio-activation of VitD, and a robust but controlled 
anti-HIV-1 response.
In summary, according to these and our previous results, 
we can postulate that natural resistance in HESNs is multi-
factorial acting progressively but also dynamically among 
several lines of defense [extensively reviewed in Ref. (25, 30)]. 
Indeed, the first line of defense could be represented by solu-
ble antiviral factors naturally produced in HESNs in higher 
amounts such as CAMP, PI3, SLPI, and defensins (3–8), which 
act inhibiting HIV-1 infection directly interacting with viri-
ons and through enhancement of specific anti-HIV-1 cellular 
mechanisms, thus preventing productive infection locally at 
the transmission site.
A second line of defense may include a cellular component 
characterized by a higher responsiveness and strong but well-
regulated immune responses. These cells could produce higher 
amounts of other antiviral proteins in response to virus such as 
those observed in this study: MX2, TRIM22, APOBEC3G, and of 
immunoregulators such as ERAP2, further preventing productive 
infection.
Finally, evidences suggest that adaptive HIV-specific immune 
responses may also be triggered in HESNs, which contribute 
with the control of the establishment of systemic infection and 
dissemination, constituting a third line of defense against HIV-1 
infection.
Importantly, VitD could favor these protective responses 
regulating immune activation in all the lines of defense.
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TaBle s1 | Details in genes analyzed. Genes symbols, primers sequences, 
the number of samples and the median and interquartile range of mRNA 
expression of each gene in each condition is detailed. The presence of putative 
VDREs in genomic regions of each gene verified in http://jaspar.genereg.net/
cgi-bin/jaspar_db.pl were also included.
FigUre s1 | Flow cytometry strategy. Sequential gating for the selection of the 
target cell populations was performed by the following way: first, a gate to exclude 
doublets was selected by using a forward-scatter height vs. forward-scatter area 
(FSC-A) plot, followed by the selection of the lymphocyte region by internal 
complexity in a side-scatter vs. FSC-A gate. For the viability staining, events 
negative of the fixable viability dye eFluor 506 were selected, whereas the 
selection of T lymphocytes was done by gating in CD3+ CD56− cells and NK cells 
were defined as CD3− CD56+ events. From the CD3+ events, gating of CD4 vs. 
CD8 was then performed for selection of CD4+ and CD8+ T lymphocytes. Finally, 
fluorescence minus one controls for TIM-3 expression were performed. 
Representative plots of CD3+ TIM+ cells under ETOH (0.01%), calcidiol (250 nM), 
and calcitriol (0.5 nM) are shown.
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